Literature DB >> 19553485

The influence of neuroactive steroid lipophilicity on GABAA receptor modulation: evidence for a low-affinity interaction.

Mariangela Chisari1, Lawrence N Eisenman, Kathiresan Krishnan, Achintya K Bandyopadhyaya, Cunde Wang, Amanda Taylor, Ann Benz, Douglas F Covey, Charles F Zorumski, Steven Mennerick.   

Abstract

Anesthetic steroids with actions at gamma-aminobutyric acid type A receptors (GABA(A)Rs) may access transmembrane domain binding site(s) directly from the plasma cell membrane. Accordingly, the effective concentration in lipid phase and the ability of the steroid to meet pharmacophore requirements for activity will both contribute to observed steady-state potency. Furthermore, onset and offset of receptor effects may be rate limited by lipid partitioning. Here we show that several GABA-active steroids, including naturally occurring neurosteroids, of different lipophilicity differ in kinetics and potency at GABA(A)Rs. The hydrophobicity ranking predicted relative potency of GABA(A)R potentiation and predicted current offset kinetics. Kinetic offset differences among steroids were largely eliminated by gamma-cyclodextrin, a scavenger of unbound steroid, suggesting that affinity differences among the analogues are dwarfed by the contributions of nonspecific accumulation. A 7-nitrobenz-2-oxa-1,3-diazole (NBD)-tagged fluorescent analogue of the low-lipophilicity alphaxalone (C17-NBD-alphaxalone) exhibited faster nonspecific accumulation and departitioning than those of a fluorescent analogue of the high-lipophilicity (3alpha,5alpha)-3-hydroxypregnan-20-one (C17-NBD-3alpha5alphaA). These differences were paralleled by differences in potentiation of GABA(A)R function. The enantiomer of C17-NBD-3alpha5alphaA, which does not satisfy pharmacophore requirements for steroid potentiation, exhibited identical fluorescence kinetics and distribution to C17-NBD-3alpha5alphaA, but was inactive at GABA(A)Rs. Simple simulations supported our major findings, which suggest that neurosteroid binding affinity is low. Therefore both specific (e.g., fulfilling pharmacophore requirements) and nonspecific (e.g., lipid solubility) properties contribute to the potency and longevity of anesthetic steroid action.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19553485      PMCID: PMC2724350          DOI: 10.1152/jn.00346.2009

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  29 in total

Review 1.  Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders.

Authors:  M Gasior; R B Carter; J M Witkin
Journal:  Trends Pharmacol Sci       Date:  1999-03       Impact factor: 14.819

Review 2.  How lipophilic cannabinergic ligands reach their receptor sites.

Authors:  Alexandros Makriyannis; Xiaoyu Tian; Jianxin Guo
Journal:  Prostaglandins Other Lipid Mediat       Date:  2005-09       Impact factor: 3.072

3.  Enantioselective modulation of GABAergic synaptic transmission by steroids and benz[e]indenes in hippocampal microcultures.

Authors:  C F Zorumski; S J Mennerick; D F Covey
Journal:  Synapse       Date:  1998-06       Impact factor: 2.562

4.  Enantioselectivity of steroid-induced gamma-aminobutyric acidA receptor modulation and anesthesia.

Authors:  L L Wittmer; Y Hu; M Kalkbrenner; A S Evers; C F Zorumski; D F Covey
Journal:  Mol Pharmacol       Date:  1996-12       Impact factor: 4.436

5.  Reversal of profound rocuronium neuromuscular blockade by sugammadex in anesthetized rhesus monkeys.

Authors:  Hans D de Boer; Jan van Egmond; Francien van de Pol; Anton Bom; Leo H D J Booij
Journal:  Anesthesiology       Date:  2006-04       Impact factor: 7.892

6.  Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis.

Authors:  Roberto C Agís-Balboa; Graziano Pinna; Adrian Zhubi; Ekrem Maloku; Marin Veldic; Erminio Costa; Alessandro Guidotti
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-19       Impact factor: 11.205

7.  Neurosteroid access to the GABAA receptor.

Authors:  Gustav Akk; Hong-Jin Shu; Cunde Wang; Joe Henry Steinbach; Charles F Zorumski; Douglas F Covey; Steven Mennerick
Journal:  J Neurosci       Date:  2005-12-14       Impact factor: 6.167

8.  Interaction between cyclodextrin and neuronal membrane results in modulation of GABA(A) receptor conformational transitions.

Authors:  Maria Pytel; Katarzyna Mercik; Jerzy W Mozrzymas
Journal:  Br J Pharmacol       Date:  2006-05-15       Impact factor: 8.739

Review 9.  Neuroactive steroids and inhibitory neurotransmission: mechanisms of action and physiological relevance.

Authors:  D Belelli; M B Herd; E A Mitchell; D R Peden; A W Vardy; L Gentet; J J Lambert
Journal:  Neuroscience       Date:  2005-11-28       Impact factor: 3.590

Review 10.  The enantiomer of cholesterol.

Authors:  E J Westover; D F Covey
Journal:  J Membr Biol       Date:  2004-11       Impact factor: 1.843

View more
  39 in total

1.  Characteristics of concatemeric GABA(A) receptors containing α4/δ subunits expressed in Xenopus oocytes.

Authors:  Hong-Jin Shu; John Bracamontes; Amanda Taylor; Kyle Wu; Megan M Eaton; Gustav Akk; Brad Manion; Alex S Evers; Kathiresan Krishnan; Douglas F Covey; Charles F Zorumski; Joe Henry Steinbach; Steven Mennerick
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model.

Authors:  Doodipala S Reddy; Michael A Rogawski
Journal:  Epilepsy Res       Date:  2010-02-20       Impact factor: 3.045

3.  Diverse voltage-sensitive dyes modulate GABAA receptor function.

Authors:  Steven Mennerick; Mariangela Chisari; Hong-Jin Shu; Amanda Taylor; Michael Vasek; Lawrence N Eisenman; Charles F Zorumski
Journal:  J Neurosci       Date:  2010-02-24       Impact factor: 6.167

4.  11-trifluoromethyl-phenyldiazirinyl neurosteroid analogues: potent general anesthetics and photolabeling reagents for GABAA receptors.

Authors:  Zi-Wei Chen; Cunde Wang; Kathiresan Krishnan; Brad D Manion; Randy Hastings; John Bracamontes; Amanda Taylor; Megan M Eaton; Charles F Zorumski; Joseph H Steinbach; Gustav Akk; Steven Mennerick; Douglas F Covey; Alex S Evers
Journal:  Psychopharmacology (Berl)       Date:  2014-04-23       Impact factor: 4.530

5.  Mapping two neurosteroid-modulatory sites in the prototypic pentameric ligand-gated ion channel GLIC.

Authors:  Wayland W L Cheng; Zi-Wei Chen; John R Bracamontes; Melissa M Budelier; Kathiresan Krishnan; Daniel J Shin; Cunde Wang; Xin Jiang; Douglas F Covey; Gustav Akk; Alex S Evers
Journal:  J Biol Chem       Date:  2018-01-04       Impact factor: 5.157

6.  Neurosteroid analogues. 18. Structure-activity studies of ent-steroid potentiators of γ-aminobutyric acid type A receptors and comparison of their activities with those of alphaxalone and allopregnanolone.

Authors:  Mingxing Qian; Kathiresan Krishnan; Eva Kudova; Ping Li; Brad D Manion; Amanda Taylor; George Elias; Gustav Akk; Alex S Evers; Charles F Zorumski; Steven Mennerick; Douglas F Covey
Journal:  J Med Chem       Date:  2013-12-24       Impact factor: 7.446

7.  Phosphatidylinositol 4,5-bisphosphate depletion fails to affect neurosteroid modulation of GABAA receptor function.

Authors:  Steven Mennerick; Amanda A Taylor; Charles F Zorumski
Journal:  Psychopharmacology (Berl)       Date:  2014-02-20       Impact factor: 4.530

8.  Kinetic and structural determinants for GABA-A receptor potentiation by neuroactive steroids.

Authors:  Gustav Akk; Douglas F Covey; Alex S Evers; Steven Mennerick; Charles F Zorumski; Joe Henry Steinbach
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

Review 9.  Neurosteroids and their role in sex-specific epilepsies.

Authors:  Doodipala Samba Reddy
Journal:  Neurobiol Dis       Date:  2014-06-21       Impact factor: 5.996

Review 10.  Neurosteroids for the potential protection of humans against organophosphate toxicity.

Authors:  Doodipala Samba Reddy
Journal:  Ann N Y Acad Sci       Date:  2016-07-23       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.